Risk adjusted net present value: What is the current valuation of CRISPR Therapeutics’s CTX-131?
CTX-131 is a gene-modified cell therapy commercialized by CRISPR Therapeutics, with a leading Phase II program in Cervical Cancer;Endometrial Cancer. …
Post
-
-
Risk adjusted net present value: What is the current valuation of Forte Biosciences’s FB-102?
FB-102 is a monoclonal antibody commercialized by Forte Biosciences, with a leading Phase I program in Celiac Disease. According to …
-
Risk adjusted net present value: What is the current valuation of Tenaya Therapeutics’s TN-401?
TN-401 is a gene therapy commercialized by Tenaya Therapeutics, with a leading Phase I program in Cardiomyopathy. According to Globaldata, …
-
Risk adjusted net present value: What is the current valuation of Solid Biosciences’s SGT-003?
SGT-003 is a gene therapy commercialized by Solid Biosciences, with a leading Phase II program in Duchenne Muscular Dystrophy. According …
-
Risk adjusted net present value: What is the current valuation of Aquestive Therapeutics’s Epinephrine?
Epinephrine is a small molecule commercialized by Aquestive Therapeutics, with a leading Phase III program in Anaphylaxis. According to Globaldata, …
-
Risk adjusted net present value: What is the current valuation of Jazz Pharmaceuticals’s JZP-898?
JZP-898 is a fusion protein commercialized by Jazz Pharmaceuticals, with a leading Phase I program in Metastatic Renal Cell Carcinoma;Metastatic …
-
Risk adjusted net present value: What is the current valuation of Vigil Neuroscience’s Iluzanebart?
Iluzanebart is a monoclonal antibody commercialized by Vigil Neuroscience, with a leading Phase III program in Neurodegenerative Diseases. According to …
-
Risk adjusted net present value: What is the current valuation of IN8bio’s INB-400?
INB-400 is a gene-modified cell therapy commercialized by IN8bio, with a leading Phase II program in Recurrent Glioblastoma Multiforme (GBM). …
-
Risk adjusted net present value: What is the current valuation of Cullinan Therapeutics’s CLN-619?
CLN-619 is a monoclonal antibody commercialized by Cullinan Therapeutics, with a leading Phase I program in Ovarian Cancer;Cervical Cancer;Endometrial Cancer. …
-
Risk adjusted net present value: What is the current valuation of Avidity Biosciences’s AOC-1020?
AOC-1020 is an antisense rnai oligonucleotide commercialized by Avidity Biosciences, with a leading Phase II program in Facioscapulohumeral Muscular Dystrophy …
-
Risk adjusted net present value: What is the current valuation of Nkarta’s NKX-19?
NKX-19 is a gene-modified cell therapy commercialized by Nkarta, with a leading Phase I program in B-Cell Chronic Lymphocytic Leukemia;Relapsed …
-
Risk adjusted net present value: What is the current valuation of IN8bio’s INB-100?
INB-100 is a gene-modified cell therapy commercialized by IN8bio, with a leading Phase I program in Myelodysplastic Syndrome. According to …
-
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co’s PR-006?
PR-006 is a gene therapy commercialized by Eli Lilly and Co, with a leading Phase II program in Frontotemporal Dementia …
-
Risk adjusted net present value: What is the current valuation of Ascendis Pharma’s TC-TLR7/8?
TC-TLR7/8 is a small molecule commercialized by Ascendis Pharma, with a leading Phase II program in Head And Neck Squamous …
-
Risk adjusted net present value: What is the current valuation of BridgeBio Pharma’s Ribitol?
Ribitol is a small molecule commercialized by BridgeBio Pharma, with a leading Phase III program in Limb-Girdle Muscular Dystrophy. According …